Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

151 results about "Inhibitory receptors" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Inhibitory Receptors. Inhibitory receptors recognize self-MHC class I molecules on target self cells, causing the activation of signaling pathways that stop the cytolytic function of NK cells. Self-MHC class I molecules are always expressed under normal circumstance.

Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof

InactiveUS20080286819A1Enhanced effector functionFunction increaseAntipyreticDigestive systemCytotoxic antibodyInhibitory receptors

The present invention provides reagents, methods and systems for predicting the cytotoxic activity of an antibody or variant thereof comprising: determining a binding affinity of the antibody or variant thereof to a Fc activating receptor; determining a binding affinity of the antibody or variant thereof to a Fc inhibitory receptor, and calculating the ratio of said activating binding affinity to said inhibitory binding affinity (A / I ratio), wherein the magnitude of said ratio is an indication of the cytotoxic activity of the antibody or variant thereof. The present invention also provides purified modified antibodies having altered A / I ratios as compared to the unmodified antibodies.

Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof

Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof

Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof

Owner:THE ROCKEFELLER UNIV

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

InactiveUS20060128689A1Pain controlBiocideNervous disorderDiseaseVanilloid receptor subtype 1

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Owner:ABBVIE INC

Heterobicyclic thiophene compounds and methods of use

ActiveUS20070197537A1Useful in treatmentBiocideNervous disorderTyrosinePharmaceutical medicine

Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Heterobicyclic thiophene compounds and methods of use

Heterobicyclic thiophene compounds and methods of use

Heterobicyclic thiophene compounds and methods of use

Owner:ARRAY BIOPHARMA

Combination immunotherapy for the treatment of cancer

ActiveUS8709417B2Improve anti-tumor effectPeptide/protein ingredientsAntibody ingredientsAgonistInhibitory receptors

Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-I, etc.) are demonstrated herein to be useful for the treatment of tumors.

Combination immunotherapy for the treatment of cancer

Combination immunotherapy for the treatment of cancer

Combination immunotherapy for the treatment of cancer

Owner:MEMORIAL SLOAN KETTERING CANCER CENT +1

Triazole derivatives useful as Axl inhibitors

ActiveUS20070213375A1BiocideSenses disorderDiseaseReceptor Protein-Tyrosine Kinases

Triazole derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

Triazole derivatives useful as Axl inhibitors

Triazole derivatives useful as Axl inhibitors

Triazole derivatives useful as Axl inhibitors

Owner:RIGEL PHARMA

Compositions and methods for modulating immune responses

InactiveUS20070054360A1Modulate activityHigh protein yieldPeptide/protein ingredientsAntibody mimetics/scaffoldsLymphocyteT cell

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Owner:ZYMOGENETICS INC

BTLA nucleic acids

InactiveUS7304149B2Decrease autoreactive lymphocyte activityEnhanced signalCell receptors/surface-antigens/surface-determinantsSugar derivativesLymphocyteInhibitory receptors

The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided.

BTLA nucleic acids

BTLA nucleic acids

BTLA nucleic acids

Owner:WASHINGTON UNIV IN SAINT LOUIS

Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

ActiveUS20080188455A1BiocideSenses disorderDiseaseReceptor Protein-Tyrosine Kinases

Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

Owner:RIGEL PHARMA

Ligands that bind a receptor

InactiveUS20080241166A1Extended half-lifeSugar derivativesAntibody mimetics/scaffoldsInhibitory receptorsReceptor degradation

The invention relates to ligands, such as immunoglobulin single variable domains, that have binding specificity for a receptor. Preferably the receptor is a cell surface receptor and / or the ligand inhibits the activity of the receptor.

Ligands that bind a receptor

Ligands that bind a receptor

Ligands that bind a receptor

Owner:DORMANTIS LTD

Inhibitors of VEGF receptor and HGF receptor signaling

ActiveUS20060074056A1Promote motilityPromote invasionBiocideOrganic chemistryVEGF receptorsHGF Receptor

The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

Inhibitors of VEGF receptor and HGF receptor signaling

Inhibitors of VEGF receptor and HGF receptor signaling

Inhibitors of VEGF receptor and HGF receptor signaling

Owner:METHYLGENE

Compositions and methods for modulating immune responses

InactiveUS20100316646A1Modulate activityHigh protein yieldPeptide/protein ingredientsAntibody mimetics/scaffoldsLymphocyteEphA Receptors

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Owner:ZYMOGENETICS INC

Heterobicyclic pyrazole compounds and methods of use

InactiveUS20070238726A1Useful in treatmentBiocideNervous disorderDiseaseMetabolite

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Heterobicyclic pyrazole compounds and methods of use

Heterobicyclic pyrazole compounds and methods of use

Heterobicyclic pyrazole compounds and methods of use

Owner:GENENTECH INC +1

Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds

InactiveUS7951819B2BiocideOrganic chemistryDiseaseMelanoma

The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds

Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds

Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds

Owner:CANCER RES TECH LTD +1

Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders

ActiveUS9067997B2Efficiently reduce or eliminate concanavalinReduce and eliminate KIR2DLBiocideAntipyreticDiseaseNatural Killer Cell Inhibitory Receptors

This invention relates to compounds that inhibit KIR2DL1, 2 and / or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2, and / or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.

Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders

Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders

Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders

Owner:INNATE PHARMA SA

Exosome transfer of nucleic acids to cells

ActiveUS20150290343A1Improve isolationEasy to modifySpecial deliveryMicroencapsulation basedGenetic MaterialsInhibitory receptors

Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.

Owner:LONZA SALES AG

Combination Immunotherapy for the Treatment of Cancer

ActiveUS20120251556A1Improve anti-tumor effectPeptide/protein ingredientsAntibody ingredientsAgonistInhibitory receptors

Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-I, etc.) are demonstrated herein to be useful for the treatment of tumors.

Combination Immunotherapy for the Treatment of Cancer

Combination Immunotherapy for the Treatment of Cancer

Combination Immunotherapy for the Treatment of Cancer

Owner:MEMORIAL SLOAN KETTERING CANCER CENT +1

Triazole derivatives useful as Axl inhibitors

ActiveUS7884119B2BiocideSenses disorderDiseaseReceptor Protein-Tyrosine Kinases

Triazole derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

Triazole derivatives useful as Axl inhibitors

Triazole derivatives useful as Axl inhibitors

Triazole derivatives useful as Axl inhibitors

Owner:RIGEL PHARMA

Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum

ActiveUS20110318429A1Inhibitory activityHeavy metal active ingredientsOrganic active ingredientsLymphatic SpreadCancer cell

The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.

Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum

Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum

Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum

Owner:MYCOMAGIC BIOTECH

Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity

ActiveUS20110256093A1Less severe osteoporosisLess severe renal failureOrganic active ingredientsPeptide/protein ingredientsDiseaseAntisense nucleic acid

Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity

Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity

Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity

Owner:LBL BIOTECH INC

Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof

InactiveUS8133485B2Senses disorderNervous disorderCell specificMast cell

Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and / or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, FcεRI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described.

Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof

Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof

Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof

Owner:DIMES - DIPARTIMENTO DO MEDICINA SPERIMENTALE - UNIV DEGLI STUDI DI GENOVA 40 +1

Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors

ActiveUS20110105512A1Antibacterial agentsBiocideReceptor Protein-Tyrosine KinasesDisease

Bridged bicyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase AxI. Methods of using the compounds in treating diseases or conditions associated with AxI activity are also disclosed.

Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors

Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors

Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors

Owner:RIGEL PHARMA

Compositions and methods for modulating immune responses

InactiveUS20090156495A1Modulate activityHigh protein yieldPeptide/protein ingredientsAntipyreticLymphocyteInhibitory receptors

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Compositions and methods for modulating immune responses

Owner:ZYMOGENETICS INC

Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors

InactiveUS20040204862A1BiocideNervous disorderDiseaseInhibitory receptors

A computer readable medium holding data of a molecular model of a ligand-gated ion channel receptor and / or a computer system for modeling said receptor are provided by the instant invention. The molecular model can be used to design novel compounds having activity as non-competitive inhibitors of the ion channel. A preferred embodiment of the invention relates to nicotinic acetylcholine receptors. Compounds having activity as non-competitive inhibitors of ligand-gated ion channel receptors and methods for inhibiting the receptor and treating diseases or disorders mediated by function of the receptor are also disclosed.

Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors

Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors

Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors

Owner:HEALTH & HUMAN SERVICES GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEPT OF THE

Method to improve the immune function of t cells

InactiveUS20150017185A1Enhance immune responseEnhancing function of T cellOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsCentral Memory T-CellP38map kinase

The present invention provides a method for enhancing the immune function of a memory T cell which comprises the step of coinhibting signalling via an inhibitory receptor which regulates T cell exhaustion and via the p38 MAP kinase signalling pathway in the T cell, and a method for treating and / or preventing an immune condition in a subject, which comprises the step of enhancing the immune function of a memory T cell in the subject by such a method. There is also provided a pharmaceutical composition or kit comprising an agent capable of inhibiting signalling via an inhibitory receptor which regulates T cell exhaustion, such as PD-1, and an agent capable of inhibiting the p38 MAP kinase signalling pathway.

Method to improve the immune function of t cells

Method to improve the immune function of t cells

Method to improve the immune function of t cells

Owner:UCL BUSINESS PLC

Compositions and methods for modulating lymphocyte activity

InactiveUS20110230647A1Antibody mimetics/scaffoldsImmunoglobulins against animals/humansLymphocyteInhibitory receptors

The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.

Compositions and methods for modulating lymphocyte activity

Compositions and methods for modulating lymphocyte activity

Compositions and methods for modulating lymphocyte activity

Owner:WASHINGTON UNIV IN SAINT LOUIS

Modulation of novel immune checkpoint targets

PendingUS20190255107A1Decrease in exhausted T cell phenotypeIncrease T cell activationAntibacterial agentsCell receptors/surface-antigens/surface-determinantsDiseaseClinical efficacy

Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network as well as novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module. This critical molecular circuit underlies the co-expression of co-inhibitory receptors in dysfunctional T cells and identifies novel regulators of T cell dysfunction.

Modulation of novel immune checkpoint targets

Modulation of novel immune checkpoint targets

Modulation of novel immune checkpoint targets

Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +2

Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

ActiveUS7803376B2Improve abilitiesImprove processing efficiencyCompound screeningApoptosis detectionTherapeutic antibodyNatural Killer Cell Inhibitory Receptors

The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.

Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

Owner:UNIV DEGLI STUDI DI PERUGIA +1

Exosome transfer of nucleic acids to cells

InactiveUS9085778B2Improve isolationEasy to modifySpecial deliveryGenetic material ingredientsGenetic MaterialsGene silencing

Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.

Owner:LONZA SALES AG

Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

ActiveUS8349838B2BiocideSenses disorderDiseaseReceptor Protein-Tyrosine Kinases

Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

Owner:RIGEL PHARMA

Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof

InactiveUS20050004080A1BiocideOrganic active ingredientsD aspartateMedicinal chemistry

Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R2 or R3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.

Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof

Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof

Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof

Owner:WYETH

Popular searches

Biology Reagent Receptor for activated C kinase 1 Toxicity Avidity Binding affinities Receptor antagonist Prodrug Receptor subtype Stereochemistry

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Patsnap Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Patsnap Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com